New York State Common Retirement Fund’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-6,100
| Closed | -$292K | – | 3225 |
|
|
2025
Q3 | $292K | Hold |
6,100
| – | – | ﹤0.01% | 2134 |
|
|
2025
Q2 | $97.5K | Hold |
6,100
| – | – | ﹤0.01% | 2682 |
|
|
2025
Q1 | $92.8K | Sell |
6,100
-3,200
| -34% | -$51.3K | ﹤0.01% | 2550 |
|
|
2024
Q4 | $189K | Hold |
9,300
| – | – | ﹤0.01% | 2322 |
|
|
2024
Q3 | $239K | Hold |
9,300
| – | – | ﹤0.01% | 2208 |
|
|
2024
Q2 | $120K | Buy |
+9,300
| New | +$150K | ﹤0.01% | 2659 |
|
|
2023
Q3 | – | Sell |
-20
| Closed | -$608 | – | 3371 |
|
|
2023
Q2 | $608 | Sell |
20
-1,460
| -99% | -$37.3K | ﹤0.01% | 3353 |
|
|
2023
Q1 | $27.8K | Hold |
1,480
| – | – | ﹤0.01% | 3080 |
|
|
2022
Q4 | $15.1K | Hold |
1,480
| – | – | ﹤0.01% | 3199 |
|
|
2022
Q3 | $39K | Buy |
1,480
+6
| +0.4% | +$219 | ﹤0.01% | 3170 |
|
|
2022
Q2 | $66K | Sell |
1,474
-5
| -0.3% | -$395 | ﹤0.01% | 3191 |
|
|
2022
Q1 | $146K | Buy |
1,479
+460
| +45% | +$43K | ﹤0.01% | 2928 |
|
|
2021
Q4 | $156K | Buy |
1,019
+250
| +33% | +$37K | ﹤0.01% | 2955 |
|
|
2021
Q3 | $104K | Buy |
769
+9
| +1% | +$1.23K | ﹤0.01% | 3130 |
|
|
2021
Q2 | $112K | Buy |
+760
| New | +$116K | ﹤0.01% | 3190 |
|
New York State Common Retirement Fund's TRML Position: Q4 2025 in Review
New York State Common Retirement Fund sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 6,100 shares — an estimated $292K sold.
New York State Common Retirement Fund first reported a position in TRML in Q2 2021 and held it in 15 quarters. The position peaked at $292K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- New York State Common Retirement Fund reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- New York State Common Retirement Fund sold 6,100 Tourmaline Bio shares in Q4 2025, an estimated $292K.
- New York State Common Retirement Fund first reported a position in Tourmaline Bio in Q2 2021 and held it in 15 quarters.
- New York State Common Retirement Fund's Tourmaline Bio position peaked at $292K in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on New York State Common Retirement Fund's 13F filing for Q4 2025, filed 12 Feb 2026.